Cargando…
Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
Immune checkpoint inhibitors, combined with anti-angiogenic agents or locoregional treatments (e.g., transarterial chemoembolization (TACE)), are expected to become standard-of-care for unresectable hepatocellular carcinoma (HCC). We measured the plasma levels of 16 soluble checkpoint proteins using...
Autores principales: | Odagiri, Naoshi, Hai, Hoang, Thuy, Le Thi Thanh, Dong, Minh Phuong, Suoh, Maito, Kotani, Kohei, Hagihara, Atsushi, Uchida-Kobayashi, Sawako, Tamori, Akihiro, Enomoto, Masaru, Kawada, Norifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464181/ https://www.ncbi.nlm.nih.gov/pubmed/32722224 http://dx.doi.org/10.3390/cancers12082045 |
Ejemplares similares
-
Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma
por: Uchida‐Kobayashi, Sawako, et al.
Publicado: (2022) -
Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma
por: Suoh, Maito, et al.
Publicado: (2020) -
Successful Transcatheter Arterial Embolization for Hemothorax from a Spontaneous Rupture of Hepatocellular Carcinoma Metastasis to the Chest Wall in an Elderly Patient
por: Suoh, Maito, et al.
Publicado: (2021) -
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
por: Kozuka, Ritsuzo, et al.
Publicado: (2022) -
High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use
por: Tamori, Akihiro, et al.
Publicado: (2020)